Technically known as glucagon-like peptide-1 receptor agonists, or GLP-1, these drugs have been around for years for treating diabetes. Now it seems most people think of GLP-1 drugs as medications to lose weight, and these medications are so popular that for a time, supply could not meet demand, leaving many to seek compounded GLP-1 medications, which were more accessible and affordable. However, compounded medications are not FDA-approved, and there are questions regarding their safety and efficacy. What do doctors and patients need to know when considering using compounded obesity medications? To help answer this, host Aaron Lohr talks with , an endocrinologist at NYU Langone Division of Endocrinology. Dr. Weintraub serves on the exam writing committee for the American Board of Obesity Medicine. Support for this episode was provided by Lilly. Show notes are available at — for helpful links or to hear more podcast episodes, visit

Bariatric surgery is a procedure used to manage obesity and obesity-related conditions. While studies have shown that bariatric surgery leads to significant weight loss, are there cases where it may be important to consider reversing the procedure? What would such cases look like? How effectively can bariatric surgery be reversed? To help explore those questions, host Aaron Lohr talks with , a second-year endocrine fellow at the University of Rochester Medical Center. She and colleagues presented an abstract at ENDO 2025 titled, “Going Backwards as a Means of Moving Forward: Severe Hypoglycemia After Bariatric Surgery.” Show notes are available at — for helpful links or to hear more podcast episodes, visit

In this episode, we take a closer look at tirzepatide, a type 2 diabetes medication also used to help with weight loss. Postmenopause weight gain can be a normal part of aging, and there are some questions about whether medications like tirzepatide could be useful and safe for postmenopausal women. Host Aaron Lohr talks with , assistant professor of medicine at Mayo Clinic Florida, and , a research fellow at Mayo Clinic College of Medicine & Science. They presented an abstract at ENDO 2025 titled, “One-Year Real-World Weight Loss Outcomes with Tirzepatide in Postmenopausal Women With and Without Hormone Therapy.” Show notes are available at — for helpful links or to hear more podcast episodes, visit

In the United States, the Food and Drug Administration doesn’t regulate supplements for safety and efficacy, so manufacturers don’t have to disclose their ingredients. We can’t always know for certain what’s in supplements we buy over the counter. Host Aaron Lohr talks with , an endocrine specialist at Ochsner Lafayette General Medical Center in Louisiana. Dr. Pattipati presented a study at ENDO 2025 in San Francisco titled, “Beware of the Hidden Ingredients and Supplement Use in Your Patients With Elevated Testosterone.” The presentation describes a case where a patient unknowingly ingested an ingredient that had a significant endocrine impact. Show notes are available at — for helpful links or to hear more podcast episodes, visit

Recently the Endocrine Society held its 12th annual Type 1 Diabetes Fellows Series program, which combines comprehensive education on type 1 diabetes with career development opportunities to build knowledge, practical skills, and a lasting network of colleagues. For this episode, host Aaron Lohr talks with , medical director of the Diabetes Institute and director of the Clinical Research Center at the University of Florida. Dr. Schatz gave a talk at the fellows series program titled, “Immunotherapies for Type 1 Diabetes: Need for Early Detection and Screening.” This year’s fellows series program and this episode were made possible by the support of Abbott Diabetes Care, CeQur Corp., Dexcom Inc., Insulet Corp., Breakthrough T1D (formerly the Juvenile Diabetes Research Foundation), Lilly USA, Mankind Pharma Limited, Medtronic Inc., Novo Nordisk Inc., and Vertex Pharmaceuticals Inc. Show notes are available at — for helpful links or to hear more podcast episodes, visit

In this episode, we cover type 1 diabetes and especially insulin delivery systems. Host Aaron Lohr talks with , from Northwestern University’s Feinberg School of Medicine and , director of education and training in diabetes technology at the Cleveland Clinic. This episode is certified for up to 0.5 AMA PRA Category 1 credits and ABIM MOC points. However, claiming those points requires taking a pre-episode test. Then you must listen to the episode on the Endocrine Society’s Center for Learning website, followed by a post-episode test and evaluation. Please check the show notes for the appropriate link. This episode is supported by educational grants by MannKind Corp. and Insulet Corp. Show notes are available at — for helpful links or to hear more podcast episodes, visit

Papillary thyroid cancer is the most common type of thyroid cancer, and yet in rare cases, this cancer may originate in locations other than the thyroid glands. In this episode, host Aaron Lohr talks about causes, prevalence, and treatment for papillary thyroid cancer and the rare phenomenon known as ectopic papillary thyroid cancer with , of University of Texas Health Science Center at Houston. Dr. Dhir and colleagues presented research at ENDO 2025 in San Francisco titled, “Where Is the Primary Papillary Thyroid Cancer?” Show notes are available at — for helpful links or to hear more podcast episodes, visit

After seven years, we have reached our 100th episode! For this, we talk about growth hormone deficiency, about causes, prevalence, why some types may become permanent, available treatments, and the importance of adherence to treatment plans. Host Aaron Lohr talks with , of Bambino Gesù Children’s Hospital in Rome, Italy. Recently, Dr. Loche and colleagues presented research at ENDO 2025 in San Francisco titled, “Adherence to GH Treatment in the Transition Age: A Prospective Study.” Show notes are available at https://www.endocrine.org/podcast/enp100 — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Recently the Endocrine Society’s Bone and Mineral Special Interest Group discussed the importance of fracture liaison services and how they contribute to an improved quality of life for patients and cost saving for the facility. An important part of the discussion revolved around a recent perspective published in titled, “Coordinating Multidisciplinary Care — Improving Outcomes after Fragility Fractures.” The article notes that despite the benefits of fracture liaison services, the lack of reimbursement for those services in the United States is a significant financial barrier, rendering the service underutilized. The article further states that the global burden of hip fractures is expected to double over the next few decades. Are we looking at an impending crisis? What role should fracture liaison services play in reducing treatment gaps and improving post-fracture care? Host Aaron Lohr talks with the three authors of that perspective: , associate professor of endocrinology and metabolism at Campus Bio-Medico University of Rome, Italy; , professor medicine at Monash University in Melbourne, Vic., Australia; and , professor of medicine at Marcus Institute for Aging Research at Hebrew Senior Life. Show notes are available at https://www.endocrine.org/podcast/enp99 — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Increased prescription of opioid medications like oxycodone and hydrocodone has led to widespread misuse of both prescription and non-prescription opioids. But did you know that opioid misuse can significantly impact the endocrine system? The Endocrine Society recently published a scientific statement titled, “Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement.” The statement reviews data on the use and misuse of opioids and discusses recent research on the endocrine-related implications of opioid use. Host Aaron Lohr talks to one of the statement’s authors, , a professor from the Institute of Metabolism and Systems Research at the University of Birmingham in the United Kingdom. Show notes are available at https://www.endocrine.org/podcast/enp98-opioids-and-the-endocrine-system — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

What treatment options are available for children and adolescents with obesity? Host Aaron Lohr takes on this topic with , associate professor in the Child Health Evaluation and Research Center at the University of Michigan, and , a clinical fellow at Cincinnati’s Children’s Hospital. Both took part in the Endocrine Society’s recent obesity fellows conference. This episode is supported by an educational grant from Lilly and Novo Nordisk. Also, this episode is available to listen for 0.5 CME credits, but you must follow the link to the show notes and read the instructions in order to earn those points. Show notes are available at https://www.endocrine.org/podcast/enp97-childhood-obesity-treatment — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast